The market for stem cell exosomes is a fast-growth, high potential market. Currently in its early-stages, the market is readily posed for expansion. With a limited number of market competitors and few products in clinical-stage trials, the market is ripe for disruption by new competitors and new technologies. [Read more…]
Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding
-
ExoCoBio is the 4th largest funded exosome startup in the world
-
ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business
SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.
[Read more…]
Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for Selective Analysis of Tumor-Derived DNA and RNA
-
Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.
-
Exosomics Siena’s technology to bring new, highly selective solutions for cancer detection, characterization and monitoring.
Siena (IT) and Basel (CH), 13 July 2018 – Exosomics Siena S.p.A., a pioneer and world leader in exosome-based diagnostics, today announced the launch of its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum. [Read more…]
Aegle Therapeutics Prepares Phase 1/2a Trial of BM-MSC Derived Extracellular Vesicles
Aegle Therapeutics Corporation is the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. Headquartered in Miami, FL, the company is using allogeneic bone marrow mesenchymal stem cell (BM-MSC) derived extracellular vesicles to treat severe dermatological disorders, with a focus on burn treatments.
In May 2018, Aegle announced that the FDA cleared its first Investigational New Drug (IND) application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.
The open label dose escalation study will enroll patients at several sites in the U.S., evaluating the safety of extracellular vesicle therapy in burn patients. [Read more…]
Geographic “Hotspots” for Exosome Clinical Trials
As exosomes become recognized for their benefits as cell-free therapeutics, exosome clinical trials are increasing in number. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, altering the function of target cells.
Exosome Clinical Trials
In addition to increasing in number, exosome clinical trials are tightly concentrated within specific regions of the world.
There are now 92 trials listed on ClinicalTrials.gov that contain the term “exosome” or “exosomes.” [Read more…]
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- Next Page »